InFlectis BioScience SAS logo

InFlectis BioScience SAS

InFlectis BioScience is a drug discovery company, developing small molecule drugs that specifically target the unfolded protein response to treat misfolding protein disorders, such as neurodegenerative and age-related diseases.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.inflectisbioscience.com
Disease Focus
STOCK CODENon Listed
Address
21 rue La Noue Bras de Fer 44200
NANTES
France
Email
Contact Number
+33 251 252 000

InFlectis BioScience is a drug discovery company, developing small molecule drugs that specifically target the unfolded protein response to treat misfolding protein disorders, such as neurodegenerative and age-related diseases.

InFlectis BioScience was co-founded by Philippe Guedat and Pierre Miniou, focusses in developing small molecule drugs that specifically target the Unfolded Protein Response (UPR) to treat misfolding protein disorders.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/inflectis-bioscience” connections=”true” suffix=””]

In Mar 2015, IInFlectis BioScience in-licenses unique protein-protein interaction drug discovery platform from Valneva (Lyon, France).

In June 2016, InFlectis BioScience raises ‹6 million in a Series A round to perform clinical trial. The financing was co-led by CM-CIC INNOVATION and REMIGES VENTURES also O CAPITAL and PARTICIPATIONS BESAN_O.

InFlectis BioScience, has completed its seed funding round, having raised ‹1.75 million to realise the potential of IFB-088 drug candidate to treat neurodegenerative diseases.